These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19718598)

  • 1. [Do biologicals have a place in the treatment of collagen diseases? Pro].
    Lorenz HM
    Dtsch Med Wochenschr; 2009 Sep; 134(36):1764. PubMed ID: 19718598
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biologicals in the treatment of rheumatic diseases].
    Scherer HU; Burmester GR
    Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
    [No Abstract]   [Full Text] [Related]  

  • 3. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
    Siddiqui MA
    Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Do biologicals have a place in the treatment of collagen diseases? Contra].
    Fleck M
    Dtsch Med Wochenschr; 2009 Sep; 134(36):1765. PubMed ID: 19718599
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biological therapy treatment of juvenile idiopathic arthritis].
    Herlin T
    Ugeskr Laeger; 2008 Jun; 170(24):2105-8. PubMed ID: 18565289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 5. B cell targeting biologics for rheumatic diseases].
    Saito K; Tanaka Y
    Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2991-7. PubMed ID: 22175143
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety issues of biologics in pregnant patients with rheumatic diseases.
    Ostensen M
    Ann N Y Acad Sci; 2014 May; 1317():32-8. PubMed ID: 24840548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
    Furst DE; Keystone EC; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop K
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i2-36. PubMed ID: 21339216
    [No Abstract]   [Full Text] [Related]  

  • 9. [Biotherapies: toward a second revolution?].
    Mouthon L
    Presse Med; 2009 May; 38(5):746-8. PubMed ID: 19328647
    [No Abstract]   [Full Text] [Related]  

  • 10. [CME. Biologics in vasculitis].
    Scharl M; Schaer D; Vallelian F
    Praxis (Bern 1994); 2015 Jan; 104(1):7-16; quiz 15. PubMed ID: 25552441
    [No Abstract]   [Full Text] [Related]  

  • 11. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ; Hyrich KL
    BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological treatment options for Graves' ophthalmopathy].
    El Fassi D; Nielsen CH; Hegedüs L
    Ugeskr Laeger; 2008 Jun; 170(24):2128-30. PubMed ID: 18565294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-cytokine therapy for connective tissue disease].
    Hayashi T; Goto D; Sumida T
    Nihon Rinsho; 2005 May; 63 Suppl 5():233-9. PubMed ID: 15954355
    [No Abstract]   [Full Text] [Related]  

  • 14. [Biologics in rheumatology].
    Wagner U
    Internist (Berl); 2019 Oct; 60(10):1036-1042. PubMed ID: 31485714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Non-TNF biologicals in therapy].
    Wollenhaupt J; Burmester GR
    Z Rheumatol; 2010 Sep; 69(7):579-80. PubMed ID: 20703491
    [No Abstract]   [Full Text] [Related]  

  • 16. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
    Furst DE; Keystone EC; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Braun J; Bresnihan B; Burmester GR; De Benedetti F; Dörner T; Emery P; Gibofsky A; Kavanaugh A; Kirkham B; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH; Winthrop K
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i2-29. PubMed ID: 19995740
    [No Abstract]   [Full Text] [Related]  

  • 17. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Organ damage in collagen vascular diseases: toward the understanding of the complicated conditions (discussion)].
    Minota S; Nara M; Kawamura H; Migita K; Sano H
    Nihon Naika Gakkai Zasshi; 2013 Oct; 102(10):2653-666; quiz 2667-70. PubMed ID: 24400547
    [No Abstract]   [Full Text] [Related]  

  • 19. [Biologics in skin diseases other than psoriasis].
    Gniadecki R; Skov L
    Ugeskr Laeger; 2008 Jun; 170(24):2126-8. PubMed ID: 18565293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
    Graves JE; Nunley K; Heffernan MP
    J Am Acad Dermatol; 2007 Jan; 56(1):e55-79. PubMed ID: 17190618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.